AL-S Pharma's AP-101 Shows Clinically Meaningful Disease Modification and Prolonged Survival in ALS Phase 2 Trial
核心洞察
AL-S Pharma (搜索)'s Phase 2 trial of AP-101, a human-derived antibody targeting misfolded SOD1 (搜索), met its primary safety endpoint and demonstrated clinically meaningful disease modification in ALS (搜索) patients.
The treatment showed prolonged survival and delayed ventilatory support with significant effects in both sporadic ALS (搜索) (p = 0.013) and SOD1 (搜索) mutation carrier cohorts (p = 0.036).
Biomarker analysis revealed reductions in key neuroaxonal injury markers including serum neurofilament light chain (搜索) and cerebrospinal fluid phosphorylated neurofilament heavy chain (搜索) after six months of treatment.
AL-S Pharma (搜索) AG announced positive results from its global Phase 2 clinical trial evaluating AP-101, an investigational human-derived antibody therapeutic targeting misfolded superoxide dismutase 1 (搜索) (SOD1 (搜索)) in patients with amyotrophic lateral sclerosis (搜索) (ALS (搜索)). The trial met its primary endpoint related to safety and tolerability while demonstrating clinically meaningful disease modification and prolonged survival supported by key biomarker improvements.
Phase 2 Trial Results Demonstrate Disease Modification
The AP-101-02 clinical trial enrolled 73 patients with both sporadic ALS (搜索) (n=52) and patients with SOD1 (搜索) gene mutations (n=21). Study participants were stratified and randomized 2:1 to receive intravenous AP-101 or placebo every three weeks. The global study was conducted across the United States, Canada, the United Kingdom, European Union, and South Korea.
A prespecified analysis of an exploratory composite endpoint revealed that early treatment with AP-101 prolonged survival and delayed ventilatory support compared to study participants receiving placebo for six months followed by six months of AP-101 treatment. Positive treatment effects were observed in both the sporadic ALS (搜索) cohort (p = 0.013) and the SOD1 (搜索) mutation carrier cohort (p = 0.036).
"These data show something we rarely see in ALS (搜索) - objective evidence of clinically meaningful disease modification that tracks directly with prolonged survival," said Dr. Angela Genge, chief medical officer of AL-S Pharma (搜索). "The Phase 2 study results with AP-101 are consistent with the hypothesis that targeting misfolded SOD1 (搜索) is a disease-modifying approach in ALS."
Biomarker Evidence Supports Clinical Findings
The clinical benefits were supported by reductions in key neuroaxonal injury biomarkers, including serum neurofilament light chain (搜索) (NfL) and cerebrospinal fluid phosphorylated neurofilament heavy chain (搜索) (pNfH) after six months of treatment. Effects on survival were accompanied by disease stabilization as measured by King's staging. Functional decline measured by ALSFRS-R was reduced in study participants with elevated misfolded SOD1 (搜索) at baseline and in SOD1 mutation carriers.
The safety profile remained favorable, with adverse events comparable to placebo and no AP-101-induced antibody responses reported throughout the study period.
Mechanism of Action and Therapeutic Approach
AP-101 is designed to selectively target the misfolded, toxic form of SOD1 (搜索) to disrupt the progressive spread of ALS (搜索) pathology in the central nervous system. The antibody helps the body's immune system clear these harmful proteins. Superoxide dismutase 1 (搜索) normally functions as a protective enzyme that helps cells manage oxidative stress, but in ALS, structural changes can cause SOD1 to lose its proper function and misfold into toxic conformations that disrupt cellular function.
Misfolded SOD1 (搜索) can injure motor neurons, damage mitochondria, and impair axonal transport, with pathology spreading through the seeding of SOD1 misfolding. This mechanism represents a therapeutic opportunity across different presentations of ALS (搜索), as misfolded SOD1 can amplify axonal injury and accelerate disease progression.
Path to Phase 3 and Regulatory Status
AL-S Pharma (搜索) is currently preparing for a confirmatory Phase 3 clinical trial of AP-101 in ALS (搜索), with initiation aimed for the end of 2026. The company has received Orphan Drug designations for AP-101 from the U.S. Food and Drug Administration, the European Medicines Agency, and Swissmedic.
The Phase 2 trial included a 24-week treatment period followed by a 24-week open-label extension where all participants received continued AP-101 treatment, and a 16-week safety follow-up period. Key assessments included survival and ventilation endpoints, slow vital capacity, neurofilament levels, misfolded SOD1 (搜索), pharmacokinetics, and anti-drug antibodies.
Dr. Genge emphasized the potential impact of these findings: "At AL-S Pharma (搜索), we believe AP-101 could fundamentally transform the treatment of ALS (搜索). We look forward to continue advancing the AP-101 clinical program so that we can bring a much-needed new treatment option to people living with ALS rapidly."